Browsing by Author Millward, Michael

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 31  next >
Issue DateTitleAuthor(s)Citation
2014Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanomaLong, Georgina; Bowyer, Samantha; Hicks, Rodney J; Lyle, Megan; McArthur, Grant A.; Millward, Michael; Raleigh, Jeanette; Rao, Aparna; Sandhu, Shahneen; Central Clinical School: The Sydney Cancer CentreActivity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma, Melanoma Research, vol.24, 5, 2014,pp 504-508
2006Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group.Millward, Michael; Bedikian, Agop Y.; Conry, Robert; DeConti, Ronald; Gore, Martin; Haluska, Frank G.; Hersey, Peter; Hersh, Evan M.; Kirkwood, John M; Pavlick, Anna C.; Pehamberger, Hubert; Trefzer, Uwe; MedicineBcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group., JOURNAL OF CLINICAL ONCOLOGY 2005, vol.24,(29),2006,pp 4738-4745
2009Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa TrialKefford, Richard (Rick); Brady, Ben; Cebon, Jonathon; Davis, Ian; Hansen, Lasse T.; Lundsgaard, Dorthe; Millward, Michael; Mouritzen, Ulrik; Skak, Kresten; Skrumsager, Birte K.; Western Clinical School: Westmead Millennium InstituteClinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial, Clinical Cancer Research, vol.15, 6,pp 2123-2129
2012Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialKefford, Richard (Rick); Long, Georgina; Arkenau, Tobias; Brown, Michael P.; et al, various; Falchook, GErald; Hamid, Omid; Infante, Jeffrey; Kim, Kevin; Kurzrock, Razelle; Millward, Michael; O'Day, Steven; Pavlick, Anna C.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreDabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial, The Lancet, vol.379, 9829, 2012,pp 1893-1901
2014Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trialStockler, Martin; Cho, Byoung Chul; Ellis, Peter; et al, Various; Leighl, Natasha; Liu, Geoffrey; Millward, Michael; Morabito, Alessandro; Perrone, F; Seymour, Lesley; Shepherd, F; Sun, Sophie; School of Public Health: NH&MRC Clinical Trials CentreDacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial, The Lancet Oncology, vol.15, 12, 2014,pp 1379-1388
2006Detection of metastatic disease in patients with uveal melanoma using positron emission tomography.Francken, A; Fulham, Michael; Millward, Michael; Thompson, John; Medicine; Central Clinical School: Medicine; Medicine; Central Clinical School: SurgeryDetection of metastatic disease in patients with uveal melanoma using positron emission tomography., European Journal of Surgical Oncology, vol.32,(7),2006,pp 780-784
2005Detection of unsuspected spinal cord compression in melanoma patients by 18F-fluorodeoxyglucose-positron emission tomography.Fulham, Michael; Hong, Angela; McCarthy, William; Millward, Michael; Thompson, John; Francken, Anne Brecht; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Surgery; Medicine; Central Clinical School: SurgeryDetection of unsuspected spinal cord compression in melanoma patients by 18F-fluorodeoxyglucose-positron emission tomography., European Journal of Surgical Oncology, vol.31,(2),2005,pp 197-204
2014Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF-inhibitor Dabrafenib (GSK2118436)Kefford, Richard (Rick); Long, Georgina; Arkenau, Hendrik-Tobias; Brown, Michael P.; Chin, Melvin; et al, .; Falchook, Gerald; Hamid, Omid; Infante, Jeffrey; Kim, Kevin; Kurzrock, Razelle; Millward, Michael; Pavlick, Anna C.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreDose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF-inhibitor Dabrafenib (GSK2118436), Clinical Cancer Research, vol.20, 17, 2014,pp 4449-4458
2016Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyCarlino, Matteo; Long, Georgina; Atkinson, Victoria; Bowyer, Samantha; et al, .; Khou, M.; Larkin, James; Lorigan, Paul; McArthur, Grant A.; Millward, Michael; Prithviraj, P.; Western Clinical School: Medicine (Westmead); Central Clinical School: The Sydney Cancer CentreEfficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy, British Journal of Cancer, vol.114, 10, 2016,pp 1084-1089
2012Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST studyBoyer, Michael; Pavlakis, Nick; Abell, Fiona; de Souza, Paul; Horwood, Keith; Johnston, Michael; Millward, Michael; Rischin, Danny; Stein, Brian; Central Clinical School: Medicine; Northern Clinical School: MedicineEfficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study, Asia Pacific Journal of Clinical Oncology, vol.8, 3, 2012,pp 248-254
2015Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testingCooper, Wendy Anne; Gill, Anthony; Pavlakis, Nick; Amanuel, Benhur; Christie, Michael; Diakos, Connie; Lum, Trina; McNeil, Catriona; Millward, Michael; Morey, Adrienne; O'Toole, Sandra; Peverall, Joanne; Selinger, Christina; Tran, Yen; Van Vliet, Chris; Waring, Paul; Central Clinical School: Medicine; Northern Clinical School: Pathology; Northern Clinical School: MedicineEquivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing, Histopathology, vol.67, 5, 2015,pp 654-663
2005Gefitinib in advanced non-small cell lung cancerBoyer, Michael; Clarke, Simon; Millward, Michael; Sharma, Rohini; Central Clinical School: Medicine; Western Clinical School: Westmead Millennium Institute; Medicine; Western Clinical School: Westmead Millennium InstituteGefitinib in advanced non-small cell lung cancer, Internal Medicine Journal 2005, vol.35,(2),2005,pp 77-82
2011Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile?Blinman, Prunella; Brown, Christopher; Duric, Vlatka; Stockler, Martin; Fong, K; McLachlan, Sue-Anne; Millward, Michael; Nowak, Anna K.; Wright, Gavin; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreLung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile?, Lung cancer, vol.72, 2, 2011,pp 213-218
2007Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinomaBoyer, Michael; Clarke, Stephen; Chuah, Benjamin; Goh, Boon-Cher; Kong, Hwai-Loong; Lim, Robert; Millward, Michael; Ong, Ai-Bee; Wong, Seng-Weng; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research InstituteMulti-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma, Acta oncologica, vol.46,(2),2007,pp 234-238
2005Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma.Joshua, A; Kefford, Richard (Rick); Millward, Michael; Aamdal, Steinar; Hersey, Peter; Lynch, Kevin; Thomson, Damien; Toner, Guy C.; Central Clinical School: Medicine; Western Clinical School: Westmead Millennium Institute; MedicineMulti-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma., Investigational New Drugs, vol.23,(3),2005,pp 253-256
2005Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.Millward, Michael; Chan, Anthony T.C.; et, al; Goh, Boon C.; Hong, Ruey-Long; Hsu, Mow-Ming; Hui, Edwin P.; Liu, Tsang-Wu; Ma, Brigette B.Y.; To, Ka F.; Whang-Peng, Jacqueline; MedicineMulticenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma., JOURNAL OF CLINICAL ONCOLOGY 2005, vol.23,(15),2005,pp 3568-3576
2006A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.Beale, Philip; Boyer, Michael; Millward, Michael; Goh, B-C; Lee, H. S.; Lee, S C; Liang, S.; Lim, H L; Soo, R. A.; Tham, L. S.; Wang, L. Z.; Yong, W P; Central Clinical School: Medicine; Central Clinical School: Medicine; MedicineA multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer., Annals of Oncology 2005, vol.17,(7),2006,pp 1128-1133
2015Patients' and doctors' preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: What makes it worthwhile?Hudson, Malcolm; Muljadi, Nick; Stockler, Martin; Veillard, Anne-Sophie; Blinman, Prunella L; Christmas, Tim; Crombie, C.; Flynn, Peter; Hughes, Brett; McLachlan, Sue-Anne; Millward, Michael; Windsor, Morgan; Wright, Gavin; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentrePatients' and doctors' preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: What makes it worthwhile?, European Journal of Cancer, vol.51, 12, 2015,pp 1529-1537
2009A Phase 2, Randomized Study of SB-485232, rhIL-18, in Patients With Previously Untreated Metastatic MelanomaKefford, Richard (Rick); Dar, Mohammed; Kathman, Steven; Kirkwood, John M; Laubscher, Kevin; Logan, Theodore F.; Mainwaring, Paul; Millward, Michael; Pavlick, Anna C.; Tarhini, Ahmad; Western Clinical School: Westmead Millennium InstituteA Phase 2, Randomized Study of SB-485232, rhIL-18, in Patients With Previously Untreated Metastatic Melanoma, Cancer, vol.115, 4,pp 859-868
2002Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibodiesClarke, Stephen; Millward, Michael; Ackland, Stephen P.; Garg, M. B.; Rischin, D.; Smith, J.; Toner, Guy C.; Zalcberg, John; Concord Clinical School: ANZAC Research Institute; MedicinePhase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibodies, Annals of Oncology, vol.13,(11),2002,pp 1810-1818